Top Nanotechnology Stocks 2026: Small Tech, Big Checks

Quick question: what do a $300 billion chipmaker, a cancer drug, and a graphene powder plant in Montreal have in common?

They all make money by pushing atoms around.

That's nanotechnology. Working with stuff between 1 and 100 nanometers, where a sheet of paper is about 100,000 nanometers thick.^[1] At that size, materials stop behaving normally. Gold turns red. Carbon gets stronger than steel. A particle of hafnium can make a tumor absorb more radiation.

So, while one might search "nanotech stocks," find a list of sleepy penny stocks with "Nano" in the name, and conclude the sector is dead... nanotech never actually went away. It just stopped calling itself nanotech and started calling itself "2nm chips," "quantum dots," "lipid nanoparticles," and "spintronics."

TSMC started high-volume 2-nanometer production at the end of 2025, and the whole industry is now racing toward 1.4nm between now and 2028. That's nanofabrication, and it's the most expensive machine upgrade cycle in chip history.

Here's the lay of the land:

• Chip nanofab: Hot. AI demand is pulling every tool vendor forward.
• Nanomaterials: Cold. Graphene and quantum dots have burned investors for 15 years.
• Nanomedicine: Warming fast. A $2.25 billion patent settlement in March made everyone re-read their LNP notes.

We're slicing this theme by where in the chain the atoms get pushed: the tools that see and build at nanoscale, the materials made at nanoscale, the devices that exploit nanoscale physics, and the medicine that delivers or activates at nanoscale. Plus a couple of private companies that matter more than most of the public ones.

You can't build what you can't see. Every 2nm chip, every quantum dot, every nanoparticle drug started on a machine that can image or pattern matter at atomic scale. These companies sell those machines, and they get paid whether the end product wins or not.

ASMLNASDAQ: ASML

You know how Nvidia sells the shovels for AI? ASML sells the shovel factory.

It's the only company on Earth that makes extreme ultraviolet lithography machines, the ones that print features a few nanometers wide onto silicon. TSMC, Samsung, and Intel all need them for 2nm and below. The next generation, called High-NA EUV, is rolling into fabs now, and each unit costs north of $350 million.

Nanofabrication is the biggest nanotech business that exists, and ASML has a monopoly on the hardest step. Boring thesis. Works anyway.

Park SystemsKRX: 140860

An atomic force microscope drags a needle with a 2-nanometer tip across a surface and maps it atom by atom. Park Systems is the world leader at building them, with about a 20% share of the global AFM market.

The founder, Sang-il Park, was in the Stanford lab that invented the AFM in 1986. The company grew revenue at a 26% compound rate from 2015 through 2025 as AFMs moved from university labs into semiconductor fabs, where chipmakers use them to check 2nm features for defects. It also bought Accurion and Lyncée Tec to add ellipsometry and holographic microscopy, so it now sells the whole nanometrology toolkit.

Korean listing, so you'll need a broker that reaches KOSDAQ. Worth the hassle.

Onto InnovationNYSE: ONTO

Onto is the less famous cousin of KLA. It sells metrology and inspection gear that measures whether a chip's nanoscale layers came out right, plus lithography tools for advanced packaging.

When nodes shrink, the number of measurement steps goes up faster than the number of wafers. Every move toward 1.4nm means more Onto tools per fab. It's a leveraged bet on the same trend as ASML, at a fraction of the market cap.

This is where nanotech got its bad reputation. Graphene was going to change everything in 2010. Quantum dots were going to be in every TV by 2016. Both took a decade longer and made a fraction of the money. Now the survivors ship product.

Nanoco GroupLSE: NANO

Nanoco makes cadmium-free quantum dots, nanocrystals that glow at exact colors depending on their size. Cadmium is toxic, and the EU restricts it, so cadmium-free matters for anything sold in Europe.

The company has been around since 2001 and has never quite broken through. But two things changed. First, it has a three-year joint development deal with an Asian chemical customer that is on track, with volumes expected to more than double next fiscal year. Second, it filed patent infringement counterclaims in January against Shoei Chemical, which bought Nanosys's quantum dot business in 2023 and supplies dots to major tech companies. Nanoco has won money from Samsung this way before.

In May, the board proposed pulling Nanoco off the London market entirely; the shares fell 41% on the day, and the June vote was shelved when it became clear the 75% needed was not there. The listing survives, for now. But a board that wants out of the public market tells you something.

Tiny company. Watch the Shoei case, the second Asian customer, and whether the delisting idea comes back.

NanoXploreTSX: GRA

NanoXplore makes graphene powder by the ton in Montreal, then mixes it into plastics and composites for trucks, buses, and packaging. It's the least glamorous graphene company and the only one with real revenue: about C$32 million last quarter, up 6% year over year, with a 23% gross margin.

The interesting part is a multi-year supply agreement with Chevron Phillips Chemical for a graphene-based lubricant additive, which management called its largest graphene powder deal ever. It also opened a plant in North Carolina, landed Club Car as a customer, and killed a $100 million anode-material project rather than burn cash on it. A founder-CEO stepped aside for a COO who talks about margins. Good sign.

The trap: revenue fell 30% the quarter before that when two big customers cut orders. Customer concentration is the risk.

Some companies don't make nanomaterials or nanotools. They just build products that only work because of nanoscale physics.

NVE CorpNASDAQ: NVEC

NVE is the strangest stock on this list: a 42-person company in Minnesota with a 79% gross margin that pays a $4 per share annual dividend.

It makes spintronic sensors and couplers, devices that read the spin of electrons instead of their charge, using magnetic layers a few atoms thick. They go into medical devices, factory automation, and defense systems. Fiscal 2026 revenue was $26.3 million, and $15.2 million of that was net income.

Growth was under 2% for the year, though, and it depends on a few big customers. You buy it for the yield and the moat.

Every mRNA COVID shot was a lipid nanoparticle. That made LNP the most profitable nanoparticle ever built. Here's who owns it, and who's next.

Arbutus BiopharmaNASDAQ: ABUS

Arbutus spent years telling anyone who'd listen that Moderna's vaccine ran on its patented lipid nanoparticle technology. In March, Moderna agreed: a $2.25 billion global settlement, with $950 million paid upfront in July and another $1.3 billion riding on an appeal. Arbutus's share of the first check was about $178 million, and it plans to return up to $230 million to shareholders.

Now it's doing the same thing to Pfizer and BioNTech, whose Comirnaty sales were roughly two-thirds of the global COVID mRNA market. Three new international lawsuits filed in July, on top of the ongoing New Jersey case where Arbutus already won a favorable claim-construction ruling.

Whoever owns the delivery nanoparticle gets paid on every drug that uses it. Plus there's an actual hepatitis B pipeline underneath.

NanobiotixNASDAQ: NBTX

Nanobiotix makes JNJ-1900, formerly NBTXR3: hafnium oxide nanoparticles injected once into a tumor. When the patient gets radiotherapy, the particles absorb the dose and dump it into the cancer cells. Johnson & Johnson licensed it in 2023 and now runs the trials.

Two catalysts this year. The pivotal head-and-neck study, NANORAY-312, got an FDA-approved protocol change that drops the interim analysis and lets the final readout happen sooner with fewer events. And the CONVERGE lung cancer study, run by J&J, showed first randomized data in March and May. A follow-on offering plus a royalty deal pushed cash runway into 2029.

Binary stock. If NANORAY-312 hits, it's a first-in-class drug with J&J's sales force. If it misses, it's a science project.

Two private companies tell you more about where nanotech is going than half the public list.

Lyten

Lyten invented a "3D graphene," a crumpled, tunable carbon that fixes the problem that killed lithium-sulfur batteries for 30 years. Li-S packs can hold twice the energy of lithium-ion and need no nickel, cobalt, or graphite.

It's raised over $1.3 billion, counts Stellantis, FedEx, and Honeywell as investors, and holds letters of intent for up to $650 million from the Export-Import Bank. Then it did something bold: it bought the assets of bankrupt Northvolt, first the Swedish factory in early 2026, and now an exclusive deal to take the German Northvolt Drei site, with a definitive agreement targeted for this quarter. Reported 2025 revenue was around $110 million.

No IPO date announced. The Series B in 2023 valued it around $1.5 billion; the Northvolt deals almost certainly pushed that higher. If it lists, it becomes the only pure-play nanomaterials company at scale on a U.S. exchange.

Zeiss SMT

Every ASML EUV machine has a set of mirrors inside it polished to within a fraction of a nanometer. Zeiss makes all of them. It began shipping its High-NA mask qualification system to fabs in February.

Zeiss is owned by a foundation and won't IPO. But if you want to know whether the High-NA cycle is on schedule, you watch Zeiss's shipment announcements, not ASML's guidance.

The name trap. Nano Dimension (NASDAQ: NNDM) is the most-searched "nanotech stock" on the internet. It's now a 3D printing company that lost $293 million last year, bought and then lost Desktop Metal to bankruptcy, and sold off its original printed-electronics business.^[2] Ticker-shopping by keyword will hurt you here more than in any other theme. Check what the company ships.

The 15-year commercialization cliff. Graphene was isolated in 2004. NanoXplore is still fighting for 20% margins. Quantum dots were commercialized in 2013; Nanoco is still fighting for customers. Nanomaterials are cheap to discover and brutal to scale. Watch for signed multi-year purchase orders with named customers, not "engagements" or JDAs.

The chip-tools side has its own risk: it's a cycle. If AI capex pauses, ASML, Park, and Onto all correct together, no matter how good the technology is.

The next 12-18 months are unusually catalyst-dense.

• Q4 2026: Nanoco full-year results and any ruling in the Shoei patent case. Lyten's definitive agreement for Northvolt Drei.
• Late 2026 to 2027: NANORAY-312 final readout for Nanobiotix, now on a shorter clock. This is the single biggest binary event on the list.
• 2027: Arbutus vs. Pfizer/BioNTech moves toward trial in New Jersey. Given what Moderna paid, the market is pricing this at almost nothing, which is either a mistake or a warning.
• 2026-2028: High-NA EUV moves from pilot to production at TSMC, Intel, and Samsung. Every quarterly shipment number from ASML and Zeiss is a data point.

The tools segment keeps compounding because AI chips need it. The materials segment stays a stock-picker's game where one signed contract can double a name. And nanomedicine is where the surprise upside lives, because LNP and radioenhancer IP is only now getting priced like the platform technology it is.

The stuff is small. The checks are not.